IMR Press / EJGO / Volume 19 / Issue 6 / pii/1998220

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up

Show Less
1 Department of Gynaecologic Oncology, The Norwegian Radium Hospital, Oslo, Norway
Eur. J. Gynaecol. Oncol. 1998, 19(6), 524–528;
Published: 10 December 1998

Objective: To evaluate the response rate, progression-free (PFS) and overall survival in patient with recurrent carcinoma of the cervix (RCC) treated with carboplatin (CBDCA; cis-diamine-1, 1-cyclobutane dicarboxylate platinum II) 300 mg/m2 or according to Calverts formula、CBDCA dose [(GFR + 25) x AUC = 51 mg intravenous (iv) day I and 5-FU (5-fluorouracil) l000 mg/m2 iv day 1 to 5 every 4 weeks. Methods: From June 1989 to October 1992, 25 patients were enrolled in this phase II study. All patients were evaluated for toxicity, response and survival data. Results: No patients obtained objective response. Eleven patients had stable disease. The median progression-free survival for these patients was 9 months (range 2 to 38), and the median survival was 17 months (range 3 - 50). For all patients the median overall survival was 11 months (range 2 - 50). Four patients survived for more than 1 year. Two of these patients survived for more than 4 years. The toxicity was tolerable with bone marrow suppression as the major problem. Conclusion: Eleven patients (44%) with RCC obtained stable disease and four patients (16%) survived for more than one year. These poor results make this combination regiment insufficient and it should not be used in treating RCC.

Back to top